USE OF THE PROSTATE HEALTH INDEX FOR DETECTION OF PROSTATE CANCER: RESULTS FROM A LARGE ACADEMIC PRACTICE

[1]  H. Moch,et al.  Urinary Biomarkers for Prostate Cancer. , 2017, Current drug metabolism.

[2]  R. Watson,et al.  Improving multivariable prostate cancer risk assessment using the Prostate Health Index , 2016, BJU international.

[3]  L. Egevad,et al.  A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. , 2016, European urology.

[4]  B. Delahunt,et al.  The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System , 2015, The American journal of surgical pathology.

[5]  John T. Wei,et al.  Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men. , 2015, Journal of Urology.

[6]  John T. Wei,et al.  The prostate health index selectively identifies clinically significant prostate cancer. , 2015, The Journal of urology.

[7]  G. Morgia,et al.  Prognostic accuracy of Prostate Health Index and urinary Prostate Cancer Antigen 3 in predicting pathologic features after radical prostatectomy. , 2015, Urologic oncology.

[8]  T. Tammela,et al.  Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up , 2014, The Lancet.

[9]  D. Bruzzese,et al.  Prostate health index vs percent free prostate-specific antigen for prostate cancer detection in men with "gray" prostate-specific antigen levels at first biopsy: systematic review and meta-analysis. , 2014, Translational research : the journal of laboratory and clinical medicine.

[10]  M. Papotti,et al.  The roles of multiparametric magnetic resonance imaging, PCA3 and prostate health index-which is the best predictor of prostate cancer after a negative biopsy? , 2014, The Journal of urology.

[11]  Ruth Etzioni,et al.  Overdiagnosis and overtreatment of prostate cancer. , 2014, European urology.

[12]  Yair Lotan,et al.  Systematic review of complications of prostate biopsy. , 2013, European urology.

[13]  A. Haese*,et al.  Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study. , 2013, European urology.

[14]  M. Nichol,et al.  Cost‐effectiveness of Prostate Health Index for prostate cancer detection , 2012, BJU international.

[15]  N. Giménez,et al.  Evaluation of [−2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis , 2012, Clinical chemistry and laboratory medicine.

[16]  F. Montorsi,et al.  Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. , 2011, European urology.

[17]  John T. Wei,et al.  A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. , 2011, The Journal of urology.

[18]  J. Tosoian,et al.  PSA and Beyond: The Past, Present, and Future of Investigative Biomarkers for Prostate Cancer , 2010, TheScientificWorldJournal.

[19]  H. Klocker,et al.  Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. , 2010, European urology.

[20]  W. Catalona,et al.  [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. , 2010, The Journal of urology.

[21]  M. Cooperberg,et al.  The changing face of prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  H. Cammann,et al.  Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer. , 2013, Clinical chemistry.